|
Mar 3
|
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
|
|
Feb 28
|
BMRN or CSLLY: Which Is the Better Value Stock Right Now?
|
|
Feb 20
|
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
|
|
Feb 14
|
Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results
|
|
Feb 14
|
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
|
|
Feb 13
|
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
|
|
Feb 12
|
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Dec 9
|
CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
|
|
Oct 2
|
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Oct 1
|
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
|
|
Sep 30
|
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
|
|
Sep 30
|
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
|
|
Sep 25
|
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
|
|
Sep 24
|
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
|
|
Jul 25
|
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Mar 30
|
10 Best Long Term ASX Stocks To Invest In
|
|
Mar 19
|
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
|
|
Feb 25
|
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued
|
|
Feb 23
|
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
|
|
Jan 31
|
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
|